Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer

Andreas Schröck, Friederike Göke, Patrick Wagner, Maike Bode, Alina Franzen, Sebastian Huss, Abbas Agaimy, Stephan Ihrler, Robert Kirsten, Glen Kristiansen, Friedrich Bootz, Claudia Lengerke, Sven Perner*

*Corresponding author for this work
21 Citations (Scopus)


Despite multimodal treatment, sinonasal malignancies have an unfavorable prognosis. The purpose of this study was to elucidate if these tumors harbor amplifications of the fibroblast growth factor receptor 1 (FGFR1) gene, which has recently been identified as a potential therapeutic target in squamous cell lung cancer. Methods. One hundred twelve primary tumors (including squamous cell carcinoma [SCC], carcinoma associated with an inverted papilloma, sinonasal undifferentiated carcinoma [SNUC], adenocarcinoma, adenoid cystic carcinoma [ACC], esthesioneuroblastoma, and 9 corresponding lymph node metastases) were assessed by fluorescence in situ hybridization (FISH) for FGFR1 copy number status. Human papillomavirus (HPV) status was assessed by p16 immunohistochemical as a surrogate marker. Results. FGFR1 amplification was found in subsets of sinonasal SCCs (20%), carcinomas associated with an inverted papilloma (33%), and SNUCs (5%). In all cases, metastatic tumor samples shared the same FGFR1 amplification status as the corresponding primary tumor tissue. None of the FGFR1-amplified tumors expressed p16. Conclusion. FGFR1 amplification represents a potential molecular target in a subset of patients with sinonasal cancer.

Original languageEnglish
JournalHead and Neck
Issue number9
Pages (from-to)1253-1257
Number of pages5
Publication statusPublished - 09.2014


Dive into the research topics of 'Fibroblast growth factor receptor-1 as a potential therapeutic target in sinonasal cancer'. Together they form a unique fingerprint.

Cite this